What question did this study set out to answer?

This study aims to evaluate the effects of maxadilan, a PAC1 receptor agonist, on corneal inflammation induced by LPS in a murine model.

July 22, 2026PLoS ONEOpen Access

PAC1 receptor agonist maxadilan alleviates corneal inflammation in a murine model of LPS-induced ocular inflammation

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the effects of maxadilan, a PAC1 receptor agonist, on corneal inflammation induced by LPS in a murine model.
Mice received systemic LPS injections followed by intravitreal maxadilan administration.
Monitored corneal health using optical coherence tomography (OCT) and tonometry.
Post-mortem analyses included cytokine profiling and corneal histological assessment.
OCT indicated significantly reduced corneal edema and improved tissue structure with maxadilan (p<0.01).
Maxadilan reduced intraocular pressure and inflammatory cell infiltration into the aqueous humor (p<0.05).
Cytokine profiling showed decreased expression of GM-CSF, IL-6, MIP-1a, TNF-a, and TREM-1 in the maxadilan group (p<0.01).

No takes yet. Share an insight, caveat, or question.

Randomized trial assesses maxadilan's impact on corneal inflammation in mice, suggesting therapeutic potential for ocular conditions.

Dobos et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark